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Background:Hepatic artery stenosis (HAS) after orthotopic liver transplantation is a signiﬁcant risk factor for subsequent
hepatic artery thrombosis (HAT). HAT is associated with a 30%-50% risk of liver failure culminating in retransplantation
or death. Traditional treatment of hepatic artery complications has been surgical, with hepatic artery revision or
retransplantation. Endovascular therapy of HAS, described primarily in the interventional radiology literature, may
provide a less-invasive treatment option.
Methods: This was a retrospective review of all endovascular interventions performed for HAS after orthotopic liver
transplantation over a 31-month period (August 2009 to January 2012). Patients with duplex ultrasound imaging
evidence of severe main HAS (peak systolic velocity of >400 cm/s, resistive index of <.5) underwent endovascular
treatment with either primary stent placement or percutaneous transluminal angioplasty (PTA) alone. Patients were
followed with serial ultrasound imaging to assess for treatment success and late restenosis. Reintervention was performed
if signiﬁcant restenosis occurred.
Results: Thirty-ﬁve hepatic artery interventions were performed in 23 patients. Over the 31-month study period, 318
orthotopic liver transplantations were performed, yielding a 7.4% (23/318) rate of hepatic artery intervention. Primary
technical success was achieved in 97% (34/35) of cases. Initial treatment was with PTA alone (n [ 10) or primary stent
placement (n[ 13). The initial postintervention ultrasound images revealed improvements in hepatic artery peak systolic
velocity (267 ± 118 [posttreatment] vs 489.9 ± 155 cm/s [pretreatment]; P < .0001) and main hepatic artery resistive
index (0.61 ± 0.08 [posttreatment] vs 0.41 ± 0.07 [pretreatment]; P < .0001). At a mean follow-up of 8.2 ± 1.8 months
(range, 0-29), there were 12 reinterventions in 10 patients for recurrent HAS. Thirty-one percent (n[ 4/13) of patients
undergoing initial stent placement required reintervention (at 236 ± 124 days of follow-up) compared with 60% (n [
6/10) of patients undergoing initial PTA (at 62.5 ± 44 days of follow-up). Primary patency rates (Kaplan-Meier) after
primary stent placement were 92%, 85%, and 69% at 1, 3, and 6 months, respectively, compared with 70%, 60%, and 50%
after PTA (P [ .17). Primary-assisted patency for the entire cohort was 97% at 6 and 12 months. Major complications
were one arterial rupture managed endovascularly and one artery dissection that precipitated HAT and required
retransplantation. The overall rate of HAT in the entire cohort was 4.3% (1/23).
Conclusions: Endovascular treatment of HAS can be performed with high technical success, excellent primary-assisted
patency, and acceptable morbidity. Initial use of a stent may improve primary patency when compared with PTA. The
need for reintervention is common, placing particular importance on aggressive surveillance. Longer follow-up and
a larger cohort are needed to conﬁrm these encouraging early results. (J Vasc Surg 2013;57:1067-72.)Hepatic artery thrombosis (HAT) is the most common
vascular complication after orthotopic liver transplantation,
with an incidence estimated to be between 4% and 11% in
adult transplants and as high as 11%-26% in the pediatric
population.1-3 Hepatic artery stenosis (HAS) is seen in
5%-11% of transplants and, if left untreated, has up to
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://dx.doi.org/10.1016/j.jvs.2012.10.086Patients with HAT have a 30%-50% incidence of eventual
liver failure, leading to retransplantation or death. Hence,
maintaining hepatic artery patency is likely an important
variable in minimizing graft loss and mortality.
Treatment of both HAS and HAT has traditionally
involved either open surgical revision of the hepatic artery
or liver retransplantation. There are several reports of
alternative approaches to this dilemma, including vein
graft interposition, endovascular thrombolysis, and mech-
anical thrombectomy.5-16 Endovascular techniques have
also been used as an alternative to open surgical repair
with less morbidity and mortality and with similar rates
of overall patient survival at 5 years (78% vs 80%, respec-
tively).4,9-11,14,16 Additionally, percutaneous transluminal
angioplasty (PTA) with or without stenting has been
found to prolong graft survival and delay the need for
open surgical revascularization or retransplantation.16
Recently, enhanced collaboration between transplant
and vascular surgeons in our institution has resulted in
a more aggressive policy of endovascular treatment of1067
Fig 1. Hepatic angiogram with an allograft coming from the main abdominal aorta before (left) and after (right)
angioplasty.
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describes the initial outcomes of this experience in treating
HAS, which began in mid-2009.
METHODS
This is a retrospective review of all endovascular inter-
ventions performed for HAS in a single tertiary care institu-
tion between August 1, 2009 and January 31, 2012. A
single vascular surgeon (W.C.S.) performed all interven-
tions. Institutional review board approval was obtained
for this study.
Deﬁnitions. Signiﬁcant HAS considered for interven-
tion was deﬁned by a main hepatic artery resistive index
(RI) <.5 and a peak systolic velocity (PSV) >400 cm/s as
detected byduplexultrasound imaging.Tardus parvuswave-
forms were usually observed in these highly stenotic hepatic
arteries. In instances where the PSV and/or RI were on the
borderline of meeting these criteria, the presence of tardus
parvus waveforms generally led to intervention.
Signiﬁcant tortuosity or kinking of the hepatic artery
was deﬁned as a >90 acute bend in the vessel, as measured
on computed tomography angiogram (CTA) or digital
subtraction angiogram.
Initial technical success was deﬁned as <30% residual
stenosis of the treated hepatic artery by visual estimation
of the ﬁnal arteriogram. Neither intravascular ultrasound
imaging nor pressure gradients were used in this series.
Diagnostic evaluation. Most patients with signiﬁcant
HAS identiﬁed by ultrasound imaging subsequently under-
went a CTA to provide additional anatomic information.
This study was found to be valuable in case planning. In
22% of our cases, the hepatic artery had an aberrant recip-
ient takeoff, either as a replaced right hepatic arising from
the superior mesenteric artery (n ¼ 2/23) or as an acces-
sory left hepatic artery with a direct takeoff from the aorta
(n ¼ 1/23) or from an infrarenal allograft (2/23; Fig 1). A
steep caudal orientation of the celiac axis was occasionally
seen, prompting a change from femoral to brachial access.
Finally, the CTA provided excellent information regarding
the relative tortuosity of the hepatic artery.The decision to intervene was based solely on the
imaging studies. Liver transaminase levels were frequently
normal in patients with signiﬁcant HAS and were therefore
not helpful in patient selection or surveillance.
Technique. Femoral access was favored unless there
was signiﬁcant caudal orientation of the celiac artery on
the CTA; in these cases, left brachial access was used.
Most femoral approach cases were performed using a 6F
renal double-curve (RDC) guiding catheter (Boston
Scientiﬁc, Natick, Mass) to gain access to the hepatic
artery. A 4F, 5F, or 6F multipurpose sheath (Cook,
Bloomingtom, Ill) was generally used with brachial access.
A 0.014-inch wire was used to cross the lesion in most
cases. Depending on the degree of tortuosity and need for
trackability, a variety of wires were used, from fairly ﬂexible
wires (Balanced Medium Weight; Abbott, Abbott Park,
Ill), to increasingly stiff hydrophilic wires (Choice PT,
Platinum Plus; Boston Scientiﬁc), to extrastiff wires
(Balanced Heavy Weight; Abbott). The stiffer wires
sometimes required placement through a quick-cross
catheter (Spectranetics, Colorado Springs, Colo), placed
previously over a softer wire. Occasionally, a second
“buddy wire” was required to further straighten a tortuous
vessel to allow delivery of a stent.
Low-proﬁle coronary angioplasty balloons were prefer-
entially used, as their trackability was much better in these
tortuous vessels. Angioplasty balloons (2.5-5.0 mm in
diameter) were sized to the nominal vessel reference size
and inﬂated for a minimum of 60 seconds. Low-proﬁle
self-expanding stents (X-pert; Abbott, 4-6 mm in diameter)
or coronary balloon-expandable stents (2.5-5.0 mm in
diameter) were used. Drug-eluting coronary stents were
selectively placed for recurrent stenosis in two patients.
Self-expanding stents were preferentially chosen when there
was a major size mismatch of the vessel proximal and distal
to the target legion. Early in our experience, we also attemp-
ted to use self-expanding stents in lesions located in highly
angulated/tortuous hepatic vessels. It was thought that
these would conform better and be less apt to create
a new “kink” distal to the stent, as a more rigid balloon-
Table I. Ultrasound ﬁndings
n
Peak systolic
velocity(cm/s)
Resistive
index
Tardus
parvus
Preintervention 35 490 0.41 83%
Postintervention 34 257 0.61 13%
1-month follow-up 29 234 0.6 16%
3-month follow-up 27 230 0.62 25%
6-month follow-up 17 243 0.68 42%
Fig 2. Kaplan-Meier curve log analysis comparing primary patency
in hepatic artery angioplasty (n ¼ 10) and stenting (n ¼ 13) (P ¼
.14). PTA, Percutaneous transluminal angioplasty.
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expanding stents in highly tortuous vessels was found to
be poor, even with stiff wires and the use of a “buddy”
wire. The coronary proﬁle balloon-expandable stents were
found to be much more trackable in these anatomic situa-
tions; their utilization increased as we gained more experi-
ence. Lesions were routinely predilated with PTA prior to
placement of a stent.
Early in our experience, PTA alone was used if a <30%
residual stenosis of the hepatic artery was achieved. Provi-
sional stenting was performed if there was a greater than
30% residual narrowing. Despite conﬁrmation of signiﬁcant
improvement in HAS by ultrasound imaging after initial
PTA, we frequently observed rapid restenosis. On the basis
of these early results, we shifted to primary stenting when
technically possible.
Postintervention protocol. Patients underwent ultra-
sound imaging at 1-7 days postintervention, then typically
at 6 weeks, 3, 6, and 12 months and yearly thereafter.
Patients with evidence of moderate recurrent stenosis
were followed more frequently. Treated patients typically
received dual-antiplatelet therapy (acetylsalicylic acid
[ASA] 81 mg and clopidogrel [Plavix] 75 mg) for 3-6
months postintervention. Clopidogrel was usually stopped
after 6 months if there was no evidence of recurrent
stenosis.
Statistics. Pre- and postintervention mean hepatic
artery PSV and RI were compared using a two-tailed t-
test. The Fischer exact test was used to compare reinter-
vention rates. Primary patency with angioplasty alone
compared with angioplasty and stent, freedom from rein-
tervention, and assisted primary patency were analyzed
using Kaplan-Meier curve log analysis. Data are presented
as means 6 standard errors.
RESULTS
Thirty-ﬁve endovascular interventions for HAS were
performed in 23 patients during the 31-month study
period. Of note, 13% (3/23) of treated patients underwent
a second orthotopic liver transplantation; all had lost their
ﬁrst liver transplant secondary to HAT. From August 2009
through January 2012, 318 liver transplants were per-
formed, with 7.2% (23/318) of patients undergoing endo-
vascular treatment for signiﬁcant HAS. No open repairs of
HAS were performed during the study period.
The mean time to initial intervention after transplanta-
tion was 92.5 6 62 days (range, 12-236). Patients had
a mean age of 49.4 6 9 years (range, 15-63), and 65%
(15/23) were male.
Ultrasound ﬁndings. Preintervention ultrasound im-
aging revealed a mean main hepatic artery PSV of 490 6
34.9 cm/s and anRI of 0.416 0.07. Initial postintervention
PSV signiﬁcantly decreased to 267 6 49 cm/s, and the RI
increased to 0.61 6 0.08 (P < .0001). These salutary
changes were sustained at 1, 3, and 6 months (Table I).
Technical success. Primary technical success was
achieved in 97% (34/35) of cases. Initial treatment was
PTA (n ¼ 10) or primary stent placement (n ¼ 13). Therewere 12 reinterventions in 10 patients for recurrent HAS.
Sixty percent (n ¼ 6/10) of patients undergoing initial
PTA required reintervention compared with 31% (n ¼
4/13) of patients undergoing initial stent placement
(P ¼ .17).
Reintervention. Time to initial reintervention was
62.5 6 44 days (range, 7-182) in those ﬁrst treated with
PTA compared with 236 6 124 days (range, 80-608) in
those initially treated with a stent (P ¼ .016). In the initial
PTA group, reinterventions were stent placements in all
patients (n ¼ 6). In the initial stent group, reinterventions
were performed with PTA alone (n ¼ 2) or with a second
stent (n ¼ 3). Although restenosis after stent placement
was most commonly observed within the stent, the culprit
lesion was occasionally adjacent to the stent.
Patency. Primary patency rates at 1, 3, and 6months by
Kaplen-Meier life-table analysis were 92%, 85%, and 69%,
respectively in the patients initially treated with a stent,
compared with 70%, 60%, and 50% in those treated with
PTA (P ¼ .17) (Fig 2; Table II). Primary patency rates for
Table II. Primary patency rates of angioplasty vs
angioplasty þ stent and overall patency rates at 1-, 3-, and
6-month follow-ups
Follow-up
Primary patency ratea
Overall primary
patency rate (n ¼ 23)
PTA
(n ¼ 10)
PTA þ stent
(n ¼ 13)
1 month 70% (n ¼ 7) 92% (n ¼ 12) 83% (n ¼ 19)
3 months 60% (n ¼ 6) 85% (n ¼ 11) 74% (n ¼ 17)
6 months 50% (n ¼ 5) 69% (n ¼ 9) 61% (n ¼ 14)
PTA, Percutaneous transluminal angioplasty.
aP ¼ .14.
Fig 3. Kaplan-Meier curve log analysis of assisted primary patency
(n ¼ 12) in patients with reinterventions; two patients had three
reinterventions.
Fig 4. Kaplan-Meier curve log analysis comparing primary patency
of hepatic arteries with kinks (n ¼ 14) with that of hepatic arteries
with no kinks (n ¼ 9) (P ¼ .5). HAS, Hepatic artery stenosis.
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months, respectively. Overall primary-assisted patency was
97% at 6 and 12 months (Fig 3). Mean follow-up of the
entire patient cohort was 8.2 6 1.8 months (range, 0-29).
Sixty-one percent (14/23) of patients had signiﬁcant
tortuosity or kink in the treated hepatic artery. Fig 4 illus-
trates the primary patency of patients with (n ¼ 14; Fig 5)
and without (n ¼ 9) tortuosity or kinks. There was not
a signiﬁcance difference between the groups at 1 and 3
months, but a trend toward inferior patency rates at 6
months in the group with signiﬁcant tortuosity or kinking
was noted.
Complications. There were two major complications
in this treatment cohort (5.7%, 2/35) and no periproce-
dural mortality. One hepatic artery rupture occurred in
a patient being retreated for HAS after initial hepatic
PTA 6 months earlier. This contained rupture was treated
with placement of a bare-metal self-expanding stent and
prolonged balloon tamponade. The patient required
a blood transfusion but did not need open surgical repair. A
follow-up CTA 4 days after the rupture revealed no hepatic
artery pseudoaneurysm, and serial ultrasound imaging
showed resolution of her high-grade HAS. Another patienthad a dissection of the hepatic artery that precipitated
HAT. This patient went on to progressive graft failure and
underwent a second successful liver transplant 1 month
later. This was the sole patient in the series who went on to
HAT, giving a rate of 4.3% (1/23) of treated patients.
Mortality. Thirty-day mortality was zero. At a mean
follow-up of 8.2 months, there was one death, yielding
a mortality rate of 4.3% (1/23). This patient had an anoxic
brain injury caused by a respiratory event 38 days after
hepatic artery intervention. In this case, the hepatic artery
was patent without signiﬁcant stenosis at the time of death.
DISCUSSION
HAS, with an incidence ranging from 4.8% to 13%, has
been recognized as a risk factor for subsequent HAT. HAT
can double the rate of biliary complications and potentially
lead to graft dysfunction.4-6,17 Appearance of a stenosis at
or near the anastomosis usually occurs secondary to opera-
tive technique or vascular clamp injury. Other causes include
allograft rejection and microvascular injury associated with
cold preservation, which are more commonly found in intra-
parenchymal vessels.18-20
HAS and HAT are diagnosed both clinically and with
Doppler ultrasound imaging. Patients presenting with elev-
ated liver transaminases, biliary leak, cholangitis, or signs of
rejection are often referred for evaluation by Doppler ultra-
sound imaging. Routine post-transplant Doppler evalua-
tions may also identify asymptomatic HAS. Vit et al21
found the presence of tardus parvus waveform to be the
most accurate individual indicator of HAS or HAT, with
a sensitivity of 91% and speciﬁcity of 99.1%.
Our series achieved an overall initial technical success
rate of 97% (34/35), which compared favorably with
Fig 5. Hepatic angiograms of a tortuous (kink) hepatic artery before (left) and after (right) angioplasty.
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81% to 100%.5,7,9,10,14,16 The major complication rate of
5.7% (2/35 interventions) in this series was comparable
to those in prior reports. Sabri et al1 reported an 8% (2/
25) need for surgical intervention after treatment for
HAS, whereas Saad et al8 reported a 4.8% (2/42) major
complication rate in patients treated with PTA.
We showed a strong trend toward improved primary
patency with initial stent placement when compared with
PTA. Because of the relatively small number of patients,
these differences did not reach statistical signiﬁcance and
likely represent a type II statistical error. Early in our expe-
rience, we frequently observed rapid restenosis of the
hepatic artery after treatment with PTA alone. These cases
typically had no residual stenosis at the completion of the
intervention, and the initial ultrasound images conﬁrmed
major improvements in lowered PSV and improved RIs.
More patients undergoing PTA alone required retreatment
compared with those receiving a primary stent (60% vs
31%), and the time to reintervention was much shorter in
PTA patients (62.5 days vs 236 days). On the basis of these
initial results, we have evolved to preferential use of primary
stenting in most instances. Our ﬁndings are concordant
with some prior reports, suggesting a beneﬁt to stenting
over angioplasty alone for HAS.4,5,10 However, the litera-
ture is not uniform in this area. In a series of 26 patients
undergoing stent placement for HAS, Ueno et al reported
that 45% of patients required reintervention for restenosis.6
A recent study by Maruzzelli et al comparing initial PTA
with stent placement found no signiﬁcant differences in
recurrent stenosis or thrombosis and mortality.11 Saad
et al opined that PTA provided better patency rates than
stent placement in properly selected patients, althoughthey did not use any stents in their series of 42 treated
patients.8
The overall primary patency rates in this series were
83%, 74%, and 61% at 1, 3, and 6 months, respectively.
Prior studies have demonstrated variable primary patency
rates. In a series of 20 patients, Chen et al reported higher
primary patency rates at 3, 6, and 12 months of 94%, 87%,
and 79%, respectively.14 However, there was a 30% need
for repeat transplantation at a median follow-up of 14.4
months. Sabri et al reported a primary patency of 52% at
4 months in 25 patients treated for HAS.1 Saad et al re-
ported a 1-year primary patency rate after angioplasty alone
(n ¼ 42) of 44%, which improved to 65% for lesions not
associated with hepatic arterial kinks.8
Signiﬁcant tortuosity and/or kinks in the hepatic artery
were seen in the majority of our patient cohort (Fig 5).
These cases were considerably more technically challenging
as detailed in under Methods. In the series from Saad et al,
PTA resulted in a 14% technical success rate in patients
with a kink, compared with 94% in those without a kink.
In his series, 5 of 57 patients were treated with primary
open surgical revision without attempt at endovascular
treatment.8 Our results in patients with signiﬁcant tortu-
osity/kinks were not signiﬁcantly worse at 1 and 3 months,
although there was a trend toward inferior primary patency
at 6 months (Fig 6). Although speculative, the better
performance in the present series may be because of stent
utilization; Saad et al8 treated exclusively with PTA.
The 4.3% (1/23) risk of HAT in our patient cohort
compared favorably with the literature. Saad et al8 reported
a 19% rate of HAT at 6 months after PTA in 42 patients.
Aggressive postintervention duplex ultrasound surveillance
and timely reintervention may have contributed to our low
Fig 6. Hepatic artery angiogram before (left) and after (right) angioplasty and stent placement.
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of signiﬁcant HAS can improve the natural history. Up to
65% of patients with untreated signiﬁcant HAS will go on
to HAT within 6 months.8
CONCLUSIONS
Endovascular treatment of HAS can be performed with
high technical success and low morbidity. Initial use of
a stent may improve primary patency when compared
with PTA. Even with stent placement, the need for reinter-
vention is common, placing particular importance on
aggressive surveillance. Timely reintervention can provide
excellent primary-assisted patency. This aggressive policy
of endovascular treatment of HAS appears to improve on
the natural history of HAS, when compared with historical
controls. Longer follow-up and a larger cohort are needed
to conﬁrm these encouraging initial ﬁndings.
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